You do not have permission to access this chart.
Please Sign Up or Login

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin’s lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of metastatic solid tumors. The company was founded in 2011 and is headquartered in Suzhou, China.






Adagene Inc. Building C14 4th Floor No. 218, Xinghu Street Suzhou Industrial Park Suzhou 25125 China



86 512 8777 3632

Leave a comment

Your email address will not be published. Required fields are marked *